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ABSTRACT
Objectives: Hot ﬂushes and night sweats (HF/NS) are
experienced by 60e70% of menopausal women and
are problematic for approximately 20e25%. Potential
health risks associated with hormone-replacement
therapy (HT) have led to a signiﬁcant decline in HT use.
There is therefore a need for safe, effective and
evidence-based alternative treatments for menopausal
symptoms. Previous exploratory work suggests that
cognitiveebehavioural therapy (CBT) is acceptable and
effective for women with HF/NS during natural
menopause and following breast-cancer treatment.
This randomised controlled trial compares the
effectiveness of Group CBT and Guided Self-Help CBT
with no treatment control in reducing HF/NS Problem
Rating and Frequency at post-treatment (main
outcome) and at 6 months postrandomisation.
Methods and analysis: 120 women, with 10 or more
HF/NS a week for a month, are recruited from GP
surgeries and the local community of South London.
They are randomised to either 4 weeks of Group CBT,
4 weeks guided Self-Help CBT or no treatment control.
Participants attend a clinical interview, and complete
baseline questionnaire measures of HF/NS Problem
Rating and Frequency (primary outcomes), mood,
quality of life, self-esteem, hot-ﬂush beliefs and
behaviours, optimism and somatic ampliﬁcation, and
undergo 24 h sternal skin conductance monitoring
(SCCdphysiological measure of HF/NS) (secondary
outcomes). Post-treatment measures (SSC,
questionnaires and use of medical services) are
collected 6e8 weeks later and follow-up measures
(questionnaires and a use of medical services
measure) at 6 months postrandomisation.
Ethics and dissemination: Ethical registration was
granted by King’s College London Research Ethics
Committee (ref: PNM/08/09-42). All participants
provide written informed consent. If treatment is
successful, a Group CBT training manual and training
sessions for health professionals, and a Self-Help CBT
book will be published. Other CBT delivery options will
also be examined (including Computerised Self-Help
CBT and Group CBT workshops).
Clinical Trial Registration Number: ISRCTN57302613.
INTRODUCTION
Menopausal symptomsdhot ﬂushes and
night sweats (HF/NS)dare experienced by
60e70% of women in Western cultures, and
are troublesome for approximately 20e25%
who seek medical help.
1 Hormone-replace-
ment therapy (HT) is an effective treatment
for HF/NS, but there are concerns about its
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ARTICLE SUMMARY
Article focus
- There is a need for safe and effective, non-
hormonal treatments for menopausal symptoms,
that is hot ﬂushes and night sweats.
- This protocol paper outlines the design of
a randomised controlled trial of self-management
psychological interventions for menopausal hot
ﬂushes and night sweats.
- The RCT aims to evaluate the effectiveness of
Group Cognitive Behaviour Therapy (CBT) and
Self-Help CBT versus no treatment control in
managing frequency and problem rating of hot
ﬂushes and night sweats.
Key messages
- This is a trial protocol.
- The study is the ﬁrst study to use both self-
report and physiological measures to examine
the effectiveness of two forms of CBT for
menopausal symptoms.
- If this treatment is successful, the interventions
can be made widely available to women using
manualised training sessions for health profes-
sionals, publication of the self-help book and
educational sessions for women.
Strengths and limitations of this study
- Strengths: the study uses both self-report and
physiological outcome measures, and aims to
recruit a diverse sample of menopausal women
from a range of backgrounds.
- Limitations: may recruit women with only very
severe hot ﬂushes, thereby reducing general-
isability to menopausal women or the population
as a whole.
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associating HT use with increased risks of breast cancer
and stroke. As a result, HTuse has fallen in the UK from
30 to 10% between 2002 and 2005.
4 Many women prefer
non-medical treatment options for these symptoms,
5 and
consequently there is an urgent need for the develop-
ment of safe, acceptable and effective non-medical
treatments to help women to manage menopausal
symptoms.
6
The aetiology of HF/NS is not clearly understood, but
they appear to be associated with the rate of change in
plasma oestrogen, which inﬂuences the thermoregula-
tory system via the hypothalamus.
7 Hot ﬂushes are also
more prevalent following rapid withdrawal of oestro-
gendfor example, following surgical menopause or
adjuvant chemotherapy for breast cancer.
8 Alterations in
oestrogen levels (but not absolute oestrogen levels) and
neurotransmitters, such as norepinephrine and sero-
tonin, and their subsequent impact on thermoregulatory
homeostasis, have been widely implicated in the patho-
genesis of HF/NS.
9e11 Freedman
12 proposes that there
is a narrowed thermoneutral zone in women who have
HF/NS, suggesting that small elevations in core body
temperature such as changes in ambient temperature or
other environmental triggers can activate HF/NS.
13 14
There is some evidence that the thermoneutral zone is
narrowed by elevated brain norepinephrine
12 15 and
general levels of stress.
14 Hot ﬂushes are often associated
with social embarrassment, anxiety, discomfort and
reduced health-related quality of life,
16 whereas night
sweats are associated with sleep problems and fatigue.
Non-medical treatments such as complementary ther-
apies are popular, but in many cases there is insufﬁcient
evidence to support their efﬁcacy.
17e19 Non-hormonal
medical treatments such as Clonidine, Megace and
Venlafaxine (SSRI) have been found to be effective but
are associated with side-effects.
20 21 In contrast, there is
some evidence that relaxation therapy and paced
breathing can reduce HF/NS.
22 23 Anxiety and negative
thoughts, associated with embarrassment, feeling out of
control and being unable to cope, have also been asso-
ciated with more frequent and problematic HF/NS.
24 25
Hunter and Liao
26 developed a four-session cognitive
behavioural treatment (CBT), which included psycho-
education, paced breathing and relaxation to reduce
stress and cognitive behavioural therapy to help women
manage HF/NS.
52 6In an initial study using a patient
preference design (no treatment vs HT vs CBT), CBT
and HT resulted in 50% reduction in hot-ﬂush
frequency, whereas there were no signiﬁcant changes
in the no-treatment group. These ﬁndings were repli-
cated in a pilot study using CBT delivered in small
groups
27 and in a recent exploratory trial of Group
CBT for breast-cancer-treatment-related menopausal
symptoms.
28 However, this form of CBT has not yet been
evaluated for HF/NS. A recent systematic review of
psychosocial interventions for HF/NS concluded that
while psycho-educational interventions are acceptable
for HF/NS, further evaluation of treatment effects
in high-quality randomised controlled trials are
required.
29
The use of self-help methods can be a cost-effective
way of delivering treatments that have limited avail-
ability.
30 Guided self-help can also address some of the
drawbacks previously ﬁelded at self-help interventions
(ie, lack of social context/social support and incorrectly
completed tasks). In a recent systematic review, guided
self-help treatments were found to be comparable with
face-to-face treatments for depression and anxiety
disorders.
31
Evaluating treatment efﬁcacy depends on valid and
reliable measures of HF/NS. Self-report measures
include daily diaries recording frequency and severity of
HF/NS and validated scales such as the Hot Flush Rating
Scale,
32 or electronic event markers. Sternal skin
conductance (SSC) monitoring is considered to be the
most valid physiological index of HF/NS.
33 The sweat
response seen in HF/NS produces a sudden increase in
skin conductivity which tails off (ie, like a swishy tail).
The use of both subjective and physiological measures
can increase our understanding of the impacts of inter-
ventions.
34 CBT may inﬂuence physiological hot ﬂushes,
women’s perceptions of hot ﬂushes or both. Twenty-four-
hour SSC hot-ﬂush monitoring has not yet been used to
evaluate menopausal treatments in the UK, but it has
been piloted and is acceptable to women.
35 36 Hunter
and Mann
34 developed a cognitive model of HF/NS that
explains how cognitive and behavioural changes might
impact on HF/NS. For example, stress and stimulants
(such as caffeine) may potentiate HF/NS in symptom-
atic women, and HF/NS may be more distressing or
interfering when they are associated with negative
thoughts such as embarrassment, social anxiety and
feeling out of control.
34
Current study
This trial aims to evaluate the effectiveness of Group
CBT and Self-Help CBT to alleviate HF/NS in women
seeking help for menopausal symptoms. It will compare
Group CBT with no treatment (control) and Self-Help
CBT with no treatment (control) in a randomised
controlled trial, with a 6-month follow-up. It is the ﬁrst
UK trial to evaluate menopause treatments using
both physiological (SSC)
35 36 and self-report measures
of HF/NS.
Speciﬁc hypothesis include:
1. Group CBT and Self-Help CBT will be more effective
than no treatment in reducing HF/NS Problem
Rating (primary outcome) and Frequency at post-
treatment.
2. Group CBT and Self-Help CBT will be more effective
than no treatment in reducing HF/NS Problem
Rating and Frequency at 6 months postrandomisation.
3. Group CBT and Self-Help CBT will be more effective
than no treatment in reducing physiological HF/NS
at post-treatment.
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An RCT of CBT for menopausal hot ﬂushes: MENOS 2 trial protocol4. Additional analyses will examine the effects of Group
CBT and Self-Help CBT on mood and quality of life
and possible moderators (optimism and somatic
ampliﬁcation) and mediators (SSC, mood, beliefs
and behaviours).
King’s College London Research Ethics Committee
approval has been granted (Psychiatry, Nursing and
Midwifery Research Ethics Subcommittee, ref: PNM/08/
09-42). The trial is registered with Current Controlled
Trials (ISRCTN57302613).
METHODS AND ANALYSIS
The study design and participant recruitment
(completed May 2010) are shown in ﬁgure 1. Partici-
pants are block-randomised to receive either no treat-
ment (access to GP support) or four weekly sessions of
Group CBT (herein referred to Group CBT) or a 4-week
guided Self-Help CBT Booklet (herein referred to
as Self-Help CBT). The Group CBT was developed
from previous work and an exploratory trial,
26 28 and
is speciﬁed in a treatment manual. Group CBT is deliv-
ered by a clinical psychologist but is designed to
be delivered by appropriately trained and supervised
health professionals. Post-treatment assessment is
conducted 6e8 weeks postrandomisation (1e3 weeks
after 4 weeks of treatment). Follow-up assessment is
conducted 6 months postrandomisation. The primary
outcome is Problem Rating of HF/NS (Hot Flush Rating
ScaledHFRS)
32 at post-treatment assessment.
Group and Self-Help CBT will be compared with the
control group separately, based on identical assump-
tions. A total sample size of 120, 40 in each group, will
have 90% power to detect a clinically relevant difference
in a mean HF/NS Problem Rating of 2 points
26
controlling for baseline value (estimated to have a mean
of 5 and SD of 2.4), a correlation between baseline and
post-treatment values of 0.4 (giving a correction factor of
0.84)
37 and a 5% two-sided signiﬁcance level.
Study sample and recruitment
One hundred and twenty participants will be recruited
from posters and leaﬂets placed in South London GP
surgeries, menopause and breast-screening clinics,
a menopause website (Menopause Matters) and news-
paper advertisements over an 18-month period from
March 2009 to May 2010. Women opt into the study by
returning a tear-off slip on the leaﬂet or through
websites, phone or email.
Inclusion criteria:
1. English-speaking women;
2. aged 18+;
3. have had problematic HF/NS for at least 1 month
(minimum frequency of 10 or more a week).
Women are excluded if they cannot understand
English or if they are currently undergoing psychiatric
treatment (ie, their psychiatric problem is the main issue
for them at the time).
Procedure
Women who opt in to the study are contacted by tele-
phone for a screening interview. A researcher conducts
an eligibility check using the above criteria and explains
the study, the three arms of the trial and the random-
isation process. Those eligible are sent a participant
information sheet, consent form, sociodemographic
questionnaire and an appointment for the baseline
assessment. The consent process is completed at the
assessment appointment, whereby the researcher
summarises the information in the participant informa-
tion sheet and responds to questions about the study.
Participants then provide written consent. The
researcher then conducts a clinical interview covering
medical history including mental health issues, meno-
pause symptoms and treatments used, concomitant
medication and therapy use, and current life concerns.
Participants are given a questionnaire to complete,
assessing HF/NS frequency and problem rating, beliefs
about HF/NS, health-related quality of life, body-image
satisfaction, self-esteem, stress, dispositional optimism
and somatic ampliﬁcation. After checking that the
participant has no allergy to adhesive dressings (eg,
plasters) and does not wear a pacemaker, the SSC hot
ﬂush monitor is ﬁtted. Participants are given a magnet
event marker, worn on a bracelet, and a 24 h hot-ﬂush
diary. They mark the experience of a HF/NS by passing
the magnet over the monitor and noting the time and
severity of the HF/NS in the diary. Participants wear the
Figure 1 Description of the overall trial design. CBT,
cognitiveebehavioural therapy.
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and removing the monitor only to shower or bathe.
Randomisation
Women are randomised in blocks of 18e30, when
sufﬁcient participants have been assessed at baseline to
enable group sizes of six to 10 participants in each arm.
Participant IDs are inputted into an internet random-
isation site and individually randomised to the three
treatment arms in the ratio 1:1:1 by the trial coordinator.
Within 2 weeks of randomisation, participants are
informed of their group allocation, and the clinical
psychologist (who delivers the CBT treatment) arranges
appointments to deliver the treatments. Assessments
take place in the Health Psychology department of
King’s College London at Guy’s Hospital. They are
conducted by the trial coordinator and a research assis-
tant who, for practical reasons, are not blind to group
allocation. Analysis is conducted by the trial statistician,
who is blind to group allocation.
Participants in the Group CBT treatment arm attend
2 h sessions of Group CBT, once a week for 4 weeks.
Women in the Self-Help CBT arm attend one introduc-
tory session with the clinical psychologist (to receive the
booklet and discuss the treatment), and complete the
booklet over 4 weeks, receiving a ‘guiding’ telephone
call from the clinical psychologist 2 weeks into treat-
ment. Participants can also contact the psychologist for
unscheduled guidance during the treatment phase.
Women from all three arms attend post-treatment
assessments in the 2 weeks following the treatment phase
(see ﬁgure 1). All participants are interviewed about
their use of health services and treatments, as well as any
changes to lifestyle and health during the treatment
phase. They complete post-treatment questionnaires and
repeat 24 h SSC hot-ﬂush monitoring. Six months after
randomisation, all participants complete a follow-up
questionnaire identical to the post-treatment question-
naire, plus use of health services and treatments, and
changes in employment, lifestyle and health over the
previous 4 months since post-treatment assessment.
Group CBT
Group CBT is interactive and psychoeducational, with
a focus on helping participants to develop strategies to
reduce stress, apply paced breathing, and cognitive and
behavioural strategies during HF/NS (see Hunter et al,
28
and Hunter and Mann
34 for detailed descriptions of the
components of CBT for HF/NS). Sessions include
information and discussion, individual goal-setting and
problem-solving, relaxation/paced-breathing practice
(using a CD) and homework. Each session takes place at
the Health Psychology department of King’s College
London at Guy’s Hospital and is run according to
a protocol set out in a treatment manual, including
presentation slides and handouts. A clinical psychologist
has been trained to deliver the treatment, and assistants
also are trained to assist in the groups. Sessions are
audio-taped, and an independent psychologist, experi-
enced in cognitive behavioural therapy, rates 10% of the
sessions for adherence to protocol using a coding sheet
created for the purpose.
Self-Help CBT
Self-Help CBT comprises four weekly sessions of
approximately 1 h. The approach and sessions are
identical to that of Group CBT, with participants
receiving a Self-Help CBT booklet and relaxation/paced
breathing CD and the same homework tasks each week.
The booklet includes interactive exercises with space for
participants to write relevant information. A clinical
psychologist trained in the delivery of the treatment
provides an information session at the beginning of
treatment. Participants are provided with the psycholo-
gist’s contact details for assistance during the 4-week
programme. Two weeks into treatment, participants
receive a telephone call from the clinical psychologist to
provide support and discuss their individual treatment
goals.
Session 1 aims to engage participants by introducing
them to the CBT model of HF/NS.
34 They are informed
about physiological, cognitive, behavioural and
emotional components of HF/NS within an overall CBT
model of menopausal symptoms and complete tasks on
stressful thinking and problem-solving techniques. Full
body relaxation and paced breathing (slow, deep and
even breathing with attentional focus on the breath) are
introduced, and participants practice relaxation for
homework.
Session 2 introduces cognitive and behavioural aspects
of hot ﬂushes. Participants revisit the CBT model, and
information about psychological processes contributing
to distress during a hot ﬂush is introduced. Participants
complete tasks on thinking and behaviour during hot
ﬂushes and problem-solve their unhelpful thoughts.
Paced breathing and cognitive behavioural strategies to
alleviate HF are discussed.
Session 3 focuses on sleep and night sweats. Partici-
pants are taught the mechanisms of sleep and cognitive
processes that inﬂuence subjective judgements of sleep
to address unhelpful cognitions, behaviours and anxi-
eties about sleep.
Session 4 reviews the overall model and goals of the
previous 3 weeks. Participants write their individual
maintenance plan.
No-treatment control
Control participants do not receive CBT treatment but
have access to their GP and other healthcare options.
Treatments and services accessed during the treatment
phase are logged at post-treatment assessment. The
control group are offered a form of CBT off-trial at the
end of the trial.
Measures
Sociodemographics
Sociodemographic variables include age, height, weight,
ethnicity, number of children, education, marital status,
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Menopausal status (as deﬁned by the Stages of Repro-
ductive Aging Workshop),
38 use of treatments for
menopause and concomitant medications and therapies
are also recorded in table 1.
Primary outcome: hot-ﬂush problem-rating
Hot-ﬂush problem-rating is a subscale of the Hot Flush
Rating Scale,
32 calculated as the mean of three items,
each measured on a 10-point scale (low to high). Items
include ‘To what extent do you regard your ﬂushes/
sweats as a problem?’; ‘How distressed do you feel about
your hot ﬂushes?’ and ‘How much do your hot ﬂushes
interfere with your daily routine?’
Secondary outcomes
Hot-ﬂush frequency and severity are assessed using the
following measures:
Hot Flush Rating Scale: frequency subscale
The frequency subscale of the HFRS is a retrospective
recording of the number of HF/NS experienced in the
previous weekdfor example, ‘How often have you had
hot ﬂushes in the past week?’ The average severity of
HF/NS over the previous week is estimated for hot
ﬂushes and for night sweats separately (1¼mild,
2¼moderate and 3¼severe).
32
Twenty-four-hour hot-ﬂush diary
Women monitor their HF/NS prospectively for 24 h.
When they experience a hot ﬂush or night sweat they
note down the severity (1¼mild, 2¼moderate and
3¼severe) and the time at which it occurred.
Twenty-four-hour ambulatory SSC and event marker
During the 24 h diary monitoring period, women wear
an ambulatory SSC monitor.
39 The monitor is approxi-
mately 636 cm, with two 8 cm electrodes attached to an
adhesive electrode patch by press studs. This electrode
patch is attached to the sternum, two inches below the
sternal notch, and holds the monitor close to the body.
Skin conductance is measured by passing a pulse
through the electrodes every 5 s, indicated by a green
ﬂash of an LED on the monitor. A hot ﬂush is deﬁned by
an increase in conductance of 2 mmhos or more in 30 s,
occurring no less than 15 min since the last SSC-deﬁned
HF/NS (ie, a 15 min lock-out period).
40 For each SSC-
deﬁned hot ﬂush or night sweat, the SSC level and the
time at which it occurred are extracted for analysis.
Women indicate that they are experiencing an HF/NS
by passing a magnet near to the monitor. The magnet is
worn on a bracelet. The times at which the magnetic
event marker is registered are summed to produce a 24 h
HF/NS subjective frequency.
Health-related quality of life
General physical and mental health are indexed using
the General Health Survey Short Form 36 (SF-36),
41
a widely used 36-item health survey. Nine physical- and
mental-health summary scales are constructed, with
a possible range from 0 to 100, where higher scores
indicate better health.
42
Table 1 Study measures
Phase
A0 baseline
assessment
Treatment
phase
A1 post-
treatment
assessment
A2 follow-up
assessment
Interview measures
Medical history, menopause symptoms, concomitant
medications and therapies
X
Questionnaire measures
Weekly diaries X*
Demographics: age, BMI, ethnicity, parity, marital status,
education, employment, smoking, drinking, exercise
X
Hot Flush Rating Scale X X* X X
Menopause representations questionnaire X X X
Hot Flush Beliefs Scale X X X
Women’s health questionnaire X X X
Rosenberg’s Self-Esteem Scale X X X
Multidimensional Body Self Relations Questionnaire X X X
Perceived Stress Scale X X X
Somatic Ampliﬁcation Scale X X X
General Health Survey Short Form 36 X X X
Life Orientation Test X
Use of services XX
CBT session evaluation X*
24 h monitoring
Sternal skin conductance X X
24 h diary X X
*Completed each week for 4 weeks by those randomised to group cognitiveebehavioural therapy (CBT) and Self-Help CBT only.
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measured using the Women’s Health Questionnaire,
43
which is standardised on samples of mid-aged women.
The WHQ contains 36 items, which are scored on four-
point scales. Nine subscales are formed by counting the
number of items scoring 2 or 3 and dividing by the
number of items for each scale, resulting in scales from
0 to 1. The WHQ has been widely used to evaluate
interventions for menopausal symptoms.
44
Process measures
Beliefs about HF/NS
HF/NS beliefs were measured using the Hot Flush
Beliefs Scale,
25 a 27-item scale comprising three
subscales including beliefs about HF in a social context,
beliefs about ability to deal with HF, and beliefs about
night sweats and sleep. An additional scale is included,
assessing behavioural reactions to HF/NS (avoidance,
safety behaviours and positive acceptance).
Perceived stress
The Perceived Stress Scale
45 measures 14 items, on
a scale from 0 (never) to 4 (very often). Items are
summed to form a scale from 0 to 56, where 0 is low
stress, and 56 is high stress.
Somatic ampliﬁcation
Barsky, Grace and Klerman’s Somatic Ampliﬁcation
Scale
46 is a 10-item scale measuring a general tendency
towards body focus, including items such as ‘When
someone else coughs, it makes me cough, too’ (1¼not
like me to 5¼very much like me). The mean for the
items is calculated to give a ﬁve-point scale, where 5 is
high somatic ampliﬁcation.
Dispositional optimism
The Revised Life Orientation Test (LOT-R)
47 measures
dispositional optimism on an eight-item scale including
‘In uncertain times, I usually expect the best’
(0¼strongly disagree to 4¼strongly agree). Items are
summed to give a total score ranging from 0 to 32, where
high scores indicate higher dispositional optimism.
Self-esteem
Rosenberg’s Self-Esteem Scale
48 measures perceived self
worth on a 10-item scale. Items are scored 1e4i nt h e
direction of negative self-esteem, and scores are summed
to give a total self-esteem score ranging from 10 to 40.
Body image
The Multi-Dimensional Body Self Relations
QuestionnairedAppearance Subscale (MBSRQ-AS)
49 is
a 34-item measure which assesses attitudes towards ones
body. It has ﬁve subscalesdappearance orientation,
appearance evaluation, overweight preoccupation,
self-classiﬁed weight and the body areas satisfaction
scaledand includes items such as ‘most people would
consider me good-looking.’ Items are presented on
a ﬁve-point scale, from 1¼deﬁnitely disagree to
5¼deﬁnitely agree, and means are calculated for the
different subscales.
Menopause representation questionnaire
The Menopause Representations Questionnaire (MRQ)
50
is a 37-item measure designed to assess women’s cogni-
tive representations (general beliefs) of the menopause
with respect to identity, consequences, time-line and
control/cure. Items are scored on a 5-point scale from
strongly agree to strongly disagree (5e1). The identity
subscale is scored from 0 to 2. The mean scores are
calculated for the subscales.
Treatment evaluation
Participants randomised to Group CBT and Self-Help
CBT are asked to rate the speciﬁc elements of the
intervention and the sessions/booklet overall. Use of the
relaxation CD, attendance and completion of homework
are also being monitored for both treatment arms at
each treatment week and through self-report on CBT
evaluation forms. At follow-up, participants are inter-
viewed by telephone or in person using open questions
to ascertain their subjective evaluation of the treatments.
This includes their perceptions of any symptom, cogni-
tive or behavioural changes occurring during treatment
or in the follow-up period, as well as their thoughts on
the group sessions/self-help booklet and how well CBT
treatment ﬁts with their lifestyle. The interviews will be
conducted, transcribed and analysed by an independent
researcher using Interpretative Phenomenological Analysis.
Analysis
An analysis plan has been agreed (ie, prior to comple-
tion of data collection). A trial statistician carries out
primary and secondary data analysis, and is blind to
group allocation. Unless indicated, scales are calculated
according to published scoring algorithms. All statistical
tests are two-sided (level of signiﬁcance¼0.05). The
outcome analyses are performed using the statistical
software SPSS version 15.0. An intention-to-treat analysis
of difference in Problem Rating HFRS between inter-
vention and control groups (Group CBT vs no treatment
or Self-Help CBT vs no treatment) is conducted using
a linear mixed model, utilising ﬁxed and random effects,
allowing for the baseline measurements to control for
pretreatment differences and clinically relevant cova-
riates. Secondary outcomes at post-treatment are
analysed similarly. Follow-up data at 6 months are also
explored through linear mixed models utilising
repeated-measures analyses, allowing simultaneous
modelling of the two outcome time points. Mediation of
treatment effects by hot-ﬂush beliefs and behaviours,
mood, self-esteem, body satisfaction, stress, quality of life
and frequency of HF/NS deﬁned by skin-conductance
rises will be explored using a two-stage least-squares
method.
51 Moderation by optimism and somatisation is
also tested using multiple-group modelling.
52
ETHICS AND DISSEMINATION
Ethical and safety considerations: some women consider
the menopause a taboo subject and may be embarrassed
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(menopause, hot ﬂushes, night sweats, etc). However, we
ensure that all potential participants are fully informed
about study materials prior to obtaining consent and
that they are given the opportunity to withdraw from the
study, should they feel uncomfortable. Women will also
be randomised into three groups, two active treatment
groups and one no-treatment group. Some participants
may be disappointed that they are not receiving
a potentially helpful treatment. However, we offer all no-
treatment participants a form of the CBT intervention at
the end of the trial. We also ensure that all participants
are fully aware of the randomisation procedure prior to
obtaining informed consent.
The SSC monitor is attached to the skin with an
adhesive electrode patch and operates with an event
marker (a magnet on a bracelet). The adhesive electrode
patch may cause irritation to those with skin allergies,
and the magnet may interfere with a pacemaker.
Participants will be asked if they have any skin allergies
or a pacemaker prior to wearing the monitor. Those who
do will not be asked to wear the monitor, and this will
not exclude them from the study.
We hope to disseminate the study through confer-
ences and journal publications. If the treatment is
successful, we plan to produce a Group CBT training
manual and training sessions for health professionals,
publish the Self-Help CBTas a book and design a further
study using a computerised version of Self-Help CBT,
and hope to examine other delivery options for the
intervention (guided vs unguided Self-Help CBT, work-
shops and 1 day, 2-day versions of Group CBT). If
effective, these interventions will enable menopausal
women with problematic HF/NS to easily access
acceptable, safe alternative treatment options. These
CBT-based interventions can also be used to enable
women to stop using HT when this is indicated.
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